- Patent Title: Manufacture of antisense oligomers and conjugates targeting PCSK9
-
Application No.: US15971951Application Date: 2018-05-04
-
Publication No.: US10370668B2Publication Date: 2019-08-06
- Inventor: Nanna Albæk , Maj Hedtjärn , Marie Wickstrom Lindholm , Niels Fisker Nielsen , Andreas Petri , Jacob Ravn
- Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
- Applicant Address: DK Hoersholm
- Assignee: Roche Innovation Center Copenhagen A/S
- Current Assignee: Roche Innovation Center Copenhagen A/S
- Current Assignee Address: DK Hoersholm
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Priority: EP13174092 20130627; EP13192930 20131114; EP13192938 20131114; WOPCT/EP2013/073858 20131114; EP14153253 20140130; EP14168331 20140514
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/02 ; C07H21/04 ; C12N15/113 ; A61K47/54 ; A61K31/712
Abstract:
The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
Public/Granted literature
- US20180312846A1 Manufacture of Antisense Oligomers and Conjugates Targeting PCSK9 Public/Granted day:2018-11-01
Information query
